American Thoracic Society International Conference 2025 (ATS 2025)
San Francisco, California, US 16 May 2025 - 21 May 2025
Nerandomilast slows IPF progression in patients already on antifibrotic therapy
The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.
First-line methotrexate on par with prednisone for sarcoidosis
The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.
BGF initiation after an exacerbation in COPD: Does timing matter?
Findings from the MITOS EROS+CP (US) study underscore the importance of prompt initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF) following an exacerbation in patients with chronic obstructive pulmonary disease (COPD).
WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma
Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.
